Travere Therapeutics logo
Travere Therapeutics
TVTX | NASDAQ
Chart Builder DCF Calculator
$49.70
-$0.95 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$49.50
-$0.20 (-0.40%)
After-hours: Nov 16, 2026, 7:46 PM ET

Travere Therapeutics Company Profile

Company profile explained

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Key Executives

Name Position
Eric Dube President, Chief Executive Officer & Director
Angela Giannantonio Chief People Officer
Christopher Cline Chief Financial Officer
Elizabeth E. Reed Chief Legal Officer, General Counsel & Secretary
Casey Logan Chief Business Officer
Jula Inrig Executive VP, Head of Research & Development and Chief Medical Officer
Nivi Nehra Vice President of Corporate Communications & Investor Relations
Peter Heerma Chief Commercial Officer
Sandra Calvin SVP & Chief Accounting Officer
William E. Rote Chief Research Officer

Latest SEC Filings

Date Type Title
Oct 19, 2026 4 Filing
Sep 21, 2026 8-K Current Report
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 11, 2026 4 Filing
View All SEC Filings ➞
Travere Therapeutics
Travere Therapeutics logo
Country United States
IPO Date Nov 8, 2012
Industry Biotechnology
Sector Healthcare
Employees 497
CEO Eric Dube

Contact Details

3611 Valley Centre Drive San Diego, California 92130 United States

Stock Details

Ticker Symbol TVTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001438533
CUSIP Number 89422G107
ISIN Number US89422G1076
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.